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Abstract
Background: Patients with the metabolic syndrome are more likely to develop type 2 diabetes and may have an
increased risk of cardiovascular disease (CVD) events.We aimed to establish whether CVD event rates were
influenced by the metabolic syndrome as defined by the World Health Organisation (WHO), the National
Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) and the International Diabetes Federation
(IDF) and to determine which component(s) of the metabolic syndrome (MS) conferred the highest cardiovascular
risk in in 4900 patients with type 2 diabetes allocated to placebo in the Fenofibrate Intervention and Event
Lowering in Diabetes (FIELD) trial.
Research design and methods: We determined the influence of MS variables, as defined by NCEP ATPIII, IDF and
WHO, on CVD risk over 5 years, after adjustment for CVD, sex, HbA1c, creatinine, and age, and interactions between
the MS variables in a Cox proportional-hazards model.
Results: About 80% had hypertension, and about half had other features of the metabolic syndrome (IDF, ATPIII).
There was no difference in the prevalence of metabolic syndrome variables between those with and without CVD
at study entry. The WHO definition identified those at higher CVD risk across both sexes, all ages, and in those
without prior CVD, while the ATPIII definition predicted risk only in those aged over 65 years and in men but not
in women. Patients meeting the IDF definition did not have higher risk than those without IDF MS.
CVD risk was strongly influenced by prior CVD, sex, age (particularly in women), baseline HbA1c, renal dysfunction,
hypertension, and dyslipidemia (low HDL-c, triglycerides > 1.7 mmol/L). The combination of low HDL-c and marked
hypertriglyceridemia (> 2.3 mmol/L) increased CVD risk by 41%. Baseline systolic blood pressure increased risk by
16% per 10 mmHg in those with no prior CVD, but had no effect in those with CVD. In those without prior CVD,
increasing numbers of metabolic syndrome variables (excluding waist) escalated risk.
Conclusion: Absence of the metabolic syndrome (by the WHO definition) identifies diabetes patients without prior
CVD, who have a lower risk of future CVD events. Hypertension and dyslipidemia increase risk.
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Patients with the metabolic syndrome (MS) events are
also more likely to develop type 2 diabetes and may
have an increased risk of future cardiovascular disease
(CVD) [1].
The most commonly used guidelines for definitions of
MS are those developed by the National Cholesterol Edu-
cation Program (NCEP) Adult Treatment Panel III
(ATPIII) in 2001 [2], the World Health Organization
(WHO) in 1999 [3], and more recently, the International
Diabetes Federation (IDF) definition [4], and the harmo-
nized definition [5]. The various components of MS do not
contribute equally to CVD risk in those without frank dia-
betes, and the relative importance of clusters of these risk
factors in the setting of established diabetes is less clear.
In the Fenofibrate Intervention and Event Lowering in
Diabetes (FIELD) study [6,7], 9795 patients with type 2
diabetes, with or without prior CVD, were recruited and
followed up for an average of 5 years. Of these, 4900
were randomized to placebo, providing a sample size
sufficient to explore whether CVD event rates were
influenced by the presence of MS components (hyper-
tension, dyslipidemia, and waist circumference) or clus-
ters, according to the 4 current definitions. This study
also allowed us to assess whether various MS compo-
nents affected the risk of CVD equally or differently in
those with and those without prior CVD and in prede-
fined age and sex subgroups.
Methods
In the FIELD study, 9795 patients with type 2 diabetes,
aged 50 to 75 years, from Australia, New Zealand, and
Finland were randomly assigned to treatment with pla-
cebo or fenofibrate for a planned duration of 5 years.
The trial has been described in detail elsewhere [6]. To
be eligible, patients had to have an initial plasma total
cholesterol level of 3.0-6.5 mmol/L, plus a total choles-
terol/HDL-c ratio of ≥ 4.0 or plasma triglyceride 1.0-5·0
mmol/L, with no clear indication for lipid-modifying
therapy at study entry. Exclusion criteria included renal
impairment (creatinine > 130 μmol/L), chronic liver dis-
ease or symptomatic gallbladder disease, and a cardio-
vascular event within 3 months before recruitment.
In this further study of FIELD participants, we exam-
ined whether the presence of MS, and its various compo-
nents, increased cardiovascular disease events over 5
years. In addition, we examined which components of
MS contributed most to cardiovascular risk. This analysis
was confined to the placebo group (n = 4900, including
1833 women), who did not receive fenofibrate during the
trial, and of whom 1016 had known CVD at study entry.
T h ep r e v a l e n c ea tb a s e l i n eo ft h eM Sc o m p o n e n t sf o r
referenced definitions (ATPIII, IDF, and WHO) was
determined (Table 1). The harmonized definition data
added nothing to the conclusions regarding the IDF defi-
nition, so were not considered further. High blood pres-
sure was defined as a self-reported history of hypertension
and documented use of medication for hypertension, or a
mean of 3 blood pressure values at baseline above 130/85
mm Hg for the IDF, ATPIII and harmonized definitions,
or above 140/90 mm Hg for the WHO definition [3-5,8].
In the WHO MS definition, dyslipidemia is a single com-
ponent, and patients can have either raised blood triglycer-
ide (≥ 1.7 mmol/L) or low HDL-c levels (< 0.9 mmol/L for
men and < 1.0 mmol/L for women). If both were present,
this was counted as a single risk factor in all analyses using
the WHO definition, whereas the other definitions allowed
each to be counted individually. Thus, if HDL-c levels
were low and triglyceride was high, both risk factors were
counted separately for IDF and ATPIII. Type 2 diabetes
was a core component for each of the definitions, and
waist measurement was included as a requirement of the
IDF definition.
O u t c o m ew a sd e f i n e da st h ef i r s tC V De v e n to v e rt h e
duration of the study (CVD death, nonfatal coronary
events, stroke, and coronary and carotid revascularizations).
Event rates for those meeting or not meeting MS cri-
teria were established in subgroups based on the prespe-
cified cut-off age of 65 years, sex, and the presence or
absence of prior CVD. The effects of baseline blood
pressure, waist circumference, HDL-c, and triglyceride
levels on CVD event rates were analysed by quintile.
Statistical analysis
We established the CVD risk associated with the various
MS components in a Cox proportional-hazards model
with categorical data from this cohort using the WHO
d e f i n i t i o n ,w i t ha d j u s t m e n tf o ra g e ,s e x ,p r i o rC V D ,
hemoglobin (Hb) A1c, and creatinine. A separate Cox
proportional-hazards model with continuous variables
was used to determine the CVD risk associated with
gradients in waist-hip ratio, blood pressure, HDL-c, tri-
glyceride concentrations, and urine albumin-creatinine
ratio, with the same adjustment variables. In both mod-
els, all possible two-way interactions between predictors
were considered for inclusion and retained if P < 0.05.
For predictors interacting with continuous variables, the
hazard ratio at the median of each continuous variable
is presented. All variables used in the analyses were
measured at study entry.
Results
Prevalence of the individual metabolic syndrome
components in the FIELD cohort
The prevalence rates of MS defined by ATPIII, IDF and
WHO 1999 are detailed in Table 1. Most participants
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sion was common. The WHO definition led to more
similar proportions of men and women having MS than
the other classifications, which identified higher preva-
lence rates of the various features in women than men,
particularly for waist criteria. There was no difference in
the prevalence of MS or its components in those with
or without CVD at study entry (data not shown).
The WHO definition was the most discriminatory for
prediction of future CVD events, and predicted higher
risks across all predefined subgroups (men and women,
age under 65 years or 65 and over, and prior CVD or
no prior CVD). (Table 2). The presence of MS by the
WHO definition conferred significantly higher CVD risk
even among patients who had prior CVD at study entry,
whereas the IDF and ATPIII definitions did not identify
this subgroup as having increased risk. ATP III criteria
were limited to identifying higher risk only in men and
those over 65 years. Furthermore, patients meeting the
IDF MS definition did not have significantly higher
CVD risk than patients without IDF MS and none of
the prespecified subgroups were associated with
increased CVD risk. These conclusions did not change if
the study population was confined to the 3837 patients
without prior CVD.
Effect of various metabolic syndrome components on
cardiovascular disease risk
The effects of metabolic-syndrome and other variables
on CVD events were modelled in a Cox regression
Table 1 Prevalence of features of metabolic syndrome at baseline in patients assigned to placebo in the FIELD study
(points of difference in criteria are shown in bold)
Feature of metabolic syndrome Men Women All patients
(n = 3067) (n = 1833) (n = 4900)
ATPIII criteria (any 3)
Diabetes or impaired fasting glucose 100 100 100
High waist measurement (M > 102 cm, F > 88 cm) 54.5 80.6 64.3
Hypertension history or BP ≥ 130/85 mmHg 82.2 85.8 83.6
High triglycerides (≥ 1.7 mmol/L) 50.0 54.1 51.5
Low HDL cholesterol (M < 1.03 mmol/L, F < 1.29 mmol/L) 54.8 66.2 59.1
Metabolic syndrome according to ATPIII 78.3 90.3 82.8
IDF criteria (waist + any 2)
Diabetes or impaired fasting glucose 100 100 100
High waist measurement (M ≥ 94 cm, F ≥ 80 cm) 83.9 95.0 88.0
Hypertension history or BP ≥ 130/85 mmHg 82.2 85.8 83.6
High triglycerides (≥ 1.7 mmol/L) 50.0 54.1 51.5
Low HDL cholesterol (M < 1.03 mmol/L, F < 1.29 mmol/L) 54.8 66.2 59.1
Metabolic syndrome according to IDF 80.5 92.5 85.0
Harmonized criteria (any 3)
Diabetes or impaired fasting glucose 100 100 100
High waist measurement (M ≥ 94 cm, F ≥ 80 cm) 83.9 95.0 88.0
Hypertension history or BP ≥ 130/85 mmHg 82.2 85.8 83.6
High triglycerides (≥ 1.7 mmol/L) 50.0 54.1 51.5
Low HDL cholesterol (M < 1.03 mmol/L, F < 1.29 mmol/L) 54.8 66.2 59.1
Metabolic syndrome according to harmonized definition 87.6 94.7 90.3
WHO criteria (diabetes + any 2)
Diabetes or impaired fasting glucose 100 100 100
High waist-hip ratio (M > 0.9, F > 0.85) or BMI > 30 88.5 80.5 85.5
Hypertension history or blood pressure ≥ 140/90 mmHg 68.5 73.3 70.3
High triglycerides (≥ 1.7 mmol/L) and/or low HDL-c (M < 0.9 mmol/L, F < 1.0 mmol/L) 58.9 59.0 58.9
Microalbuminuria (urine albumin/creatinine ≥ 3.4 mg/mmol) 23.6 20.8 22.6
Metabolic syndrome according to WHO 82.6 80.7 81.9
* IDF criteria for hypertension, high triglyceride, and low HDL-c are the same as those for ATPIII.
† Harmonized criteria are the same as for IDF except metabolic syndrome does not require high waist measurement.
‡ Ethnic and sex-specific cut-offs for waist circumference define high risk in the harmonized definition. This analysis, for a population mainly of European origin,
used the “Caucasian” waist cut-off.
FIELD, Fenofibrate Intervention and Event Lowering in Diabetes; ATPIII, Adult Treatment Panel III; M, male; F, female; BP, blood pressure; IDF, International
Diabetes Federation; WHO, World Health Organization; HDL-c, high-density lipoprotein cholesterol
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CVD, baseline HbA1c, and creatinine had major influ-
ences on CVD outcomes. The effects of MS variables on
CVD events were calculated after adjustment for these
variables. While increases in triglyceride (0.5 mmol/L)
and waist circumference (10 cm) did not have significant
effects, both a decrease of HDL-c and an increase in sys-
tolic BP were associated with significant CVD
disadvantage.
Hypertension in patients without prior CVD more than
doubled CVD risk in a categorical Cox regression model
(data not shown). In those without prior CVD, increasing
numbers of MS variables escalated risk regardless of the
MS definition being applied (Figure 1); those with diabetes
plus all MS components had two to three times the risk of
those with diabetes alone (regardless of definition).
The CVD risk of the 1063 patients with prior CVD was
25-26% if they met criteria for MS (any of the definitions;
Table 2). Prior CVD roughly tripled the risk of future
events in this group compared with those without prior
CVD, even when up to two MS risk factors were present.
Increasing numbers of MS variables in those with prior
CVD did not so clearly increase risk (Table 2, Figure 1).
MS variables by quintile and CVD events
Men had a higher CVD risk if their HDL-c was below
0.95 mmol/L. No strong gradient of risk was observed
for women, although those with HDL-c < 0.98 mmol/L
Table 2 Total CVD event rates (%, 95% CI) by presence of metabolic syndrome with different definitions in patients
assigned to placebo in the FIELD study
ATPIII IDF Harmonized Who
Group No MS MS Diff (95% CI) No MS MS Diff (95% CI) No MS MS Diff (95% CI) No MS MS Diff (95% CI)
Age ≥ 65 12 19 7 (3-11)‡ 15 18 3 (-2-7) 11 18 7 (2-12)† 8 19 11 (8-14)‡
Age < 65 11 12 0 (-3-3) 13 11 -2 (-5-2) 11 12 0 (-3-4) 7 12 5 (3-8) ‡
Male 12 18 6 (3-9)‡ 16 17 1 (-2-5) 12 17 5 (2-9)† 9 18 9 (6-12) ‡
Female 9 10 1 (-4-5) 7 10 2 (-2-7) 7 10 2 (-3-8) 5 11 5 (2-8) ‡
Prior CVD 22 26 3 (-4-10) 26 25 -1 (-9-6) 19 26 7 (-2-16) 18 26 8 (0-15)*
No prior CVD 9 11 2 (-0-5) 11 11 -0 (-3-3) 10 11 1 (-2-4) 6 12 6 (4-8) ‡
All patients 11 14 3 (1-5)* 14 14 -0 (-3-3) 11 14 3 (0-6)* 8 15 8 (5-10) ‡
*P < 0.05, †P < 0.01, ‡P < 0.001 for the absolute risk difference for metabolic syndrome compared with no metabolic syndrome. The larger the difference, the
greater the risk discrimination provided by the definition.
CVD, cardiovascular disease; FIELD, Fenofibrate Intervention and Event Lowering in Diabetes; MS, metabolic syndrome; ATPIII, Adult Treatment Panel III; IDF,
International Diabetes Federation; WHO, World Health Organization;
Table 3 Cox regression model* for the effect of continuous variables, including features of the metabolic syndrome as
defined by ATPIII, on the risk of total CVD events in patients assigned to placebo in the FIELD study
Variable† Hazard ratio (95% CI) P
Predictive variable
Female (at 62 years) 0.70 (0.55-0.88) 0.003
Age (per 10 years): male 1.21 (1.06-1.39) < 0.001
Age (per 10 years): female 1.74 (1.38-2.19)
Prior CVD (at 140 mmHg SBP, 6.85% HbA1c) 2.14 (1.81-2.53) < 0.001
Hemoglobin A1c (per 1%): no prior CVD 1.18 (1.10-1.26) < 0.001
Hemoglobin A1c (per 1%): prior CVD 1.03 (0.95-1.13)
Creatinine (per 20 μmol/L) 1.21 (1.09-1.35) < 0.001
Metabolic syndrome variable‡
Waist -hip ratio (per 0.1) 1.03 (0.91-1.17) 0.60
Systolic BP (per 10 mmHg): no prior CVD 1.16 (1.09-1.24) < 0.001
Systolic BP (per 10 mmHg): prior CVD 1.01 (0.94-1.09)
Triglycerides (per 0.5 mmol/L) 1.03 (0.99-1.07) 0.19
HDL-c (per 0.1 mmol/L) 0.94 (0.90-0.97) < 0.001
Urine albumin-creatinine ratio (per doubling) 1.06 (1.02 - 1.10) 0.002
* Cox proportional-hazards assumptions were met.
† All variables were centered at medians. Standard deviations for distributions of the continuous variables were: age, 6.9 years; HbA1c, 1.35%; creatinine, 15.8
μmol/L; waist, 13 cm; systolic BP, 15 mmHg; triglycerides, 0.88 mmol/L; HDL-c, 0.26 mmol/L.
‡ Corrected for age, sex, prior CVD, baseline HbA1c and creatinine.
ATPIII, Adult Treatment Panel III; CVD, cardiovascular disease; FIELD, Fenofibrate Intervention and Event Lowering in Diabetes; BP, blood pressure; HDL-c, high-
density lipoprotein cholesterol
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mmol/L (Figure 2). For men, a progressive rise in risk
occurred as triglyceride levels rose through the quintiles.
For women, there was no significant risk gradient. Base-
line systolic BP was associated with CVD risk in both
sexes across quintiles, but waist measurements were not
significantly associated with risk.
Discussion
In the placebo cohort of FIELD, the absolute risk of a
CVD event was higher in those with more MS compo-
nents, provided they did not have prior CVD. Patients
with prior CVD had a less clear risk gradient related to
the presence or absence of MS features.
The WHO definition of metabolic syndrome outper-
formed the other definitions in predicting CVD. It does
not include waist measurement, which was not a signifi-
cant risk factor in any case (replaced by waist-hip ratio
and also not a significant risk factor). Its hypertension
cut-off is higher than that of the other definitions, and
it combines the triglyceride criterion (not predictive in
women) with the lower and sex-specific HDL-c criter-
ion. Our findings are in line with those of the Strong
Heart Study, also in diabetes, with the WHO definition
performing best[9].
T h ep r e v a l e n c eo fM Sf e a t u r e s ,a sd e f i n e db yA T P I I I ,
IDF, and WHO classifications, was high, particularly for
treated hypertension or high blood pressure at study
entry. Over 80% met MS criteria irrespective of defini-
tion, and 60% had at least 3 MS components, in addi-
tion to type 2 diabetes.
The protective effect of sex was strong, with women
having a 30% lesser CVD risk than men, after adjust-
ment. This is consistent with previous reports, first, that
type 2 diabetes doubles in men and triples in women
the relative risk of various CVD events [10,11], and sec-
ond, that men with MS are more likely to have a CVD
event than women [12,13]. However, there are also
some reports that women are at higher risk of CVD
than men [14,15]. In FIELD, for every 10 years of age, at
0
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Figure 1 Cardiovascular disease event rates according to the number of additional metabolic syndrome components (risk factors) at
baseline in relation to the ATPIII, IDF, harmonized, and WHO categories in patients allocated to placebo without (n = 3837) or with (n
= 1063) prior cardiovascular disease. Apparent high event rates in the groups with no additional risk factors by the harmonized and WHO
definitions are an artifact of low patient numbers.
Scott et al. Cardiovascular Diabetology 2011, 10:102
http://www.cardiab.com/content/10/1/102
Page 5 of 8baseline, CVD risk was 74% higher in women and 21%
higher in men. Although truncal obesity was prevalent,
particularly in women, high waist circumference and
waist-hip ratio were not significant CVD risk factors, in
contrast to other studies in more general populations
[16,17]. This may reflect the greater importance of this
component in a prediabetes setting. Although truncal
fat is an important driver of insulin resistance [18], and
adjustment for WHR has been shown, for example, to
influence the relationship of HOMA-index with left ven-
tricular mass in people without diabetes [19], once dia-
b e t e si sp r e s e n t ,i ti sp o s s i b l et h a te x c e s st r u n c a lf a tn o
longer predicts future CVD events. However, fatness,
adipocytokine release and inflammation are tightly inter-
linked, and an effect on CVD event rates would have
been predicted [20,21]. The most important MS predic-
tor of CVD events in the Framingham Offspring Study
was blood pressure [13], followed by HDL-c level, and
not waist measurement, consistent with the findings of
this FIELD analysis. Waist circumference is a required
component of the IDF definition, which may explain its
lesser discrimination of risk in comparison with the har-
monized version. Of interest, another group has
reported an association between prevalence of MS and
higher levels of within-normal-limits liver function [22].
The presence of dyslipidemia contributed to CVD risk.
All MS definitions apply sex-specific levels for HDL-c,
with the triglyceride level set at 1.7 mmol/L, above
which LDL particles tend to be of smaller size and
greater density, properties that reflect higher atherogeni-
city [23]. In the FIELD cohort, there was a gradient of
risk as triglyceride levels increased above 1.5 mmol/L in
men, but in women no change in risk was observed
across the quintiles except for a suggestion of higher
risk at levels over 2.5 mmol/L. These data support the
possibility of a triglyceride risk differential by sex in dia-
betes, although this was not the finding of the recent
meta-analysis of the Emerging Risk Factors Collabora-
tion [24]. It would appear that there is also a strong sex
difference with respect to cut-offs for the HDL-c levels
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Men <1.2 1.2–1.5 1.5–1.9 1.9–2.5 >2.5
Women <1.3 1.3–1.6 1.6–1.9 1.9–2.5 >2.5
<0.9 0.9–1.0 1.0–1.1 1.1–1.2 >1.2
<1.0 1.0–1.1 1.1–1.2 1.2–1.4 >1.4
Men <127 127–136 136–143 143–153 >153
Women <127 127–137 137–143 143–153 >153
<95 95–100 101–107 107–114 >114
<89 89–96 96–103 103–112 >112
Figure 2 Cardiovascular disease event rates according to quintiles of baseline triglycerides, HDL-c, systolic blood pressure, and waist
circumference in men and women allocated to placebo.
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ciated with HDL-c levels below 0.95 mmol/L, a value
similar to that used in these definitions of MS. In
women, the FIELD data suggest that the defined levels
for HDL-c should be set lower than specified by ATPIII
(for example, < 1.0 mmol/L) to select diabetes patients
with higher CVD risk. This m a yp a r t l ye x p l a i nw h yt h e
WHO definition came out as the most predictive
(although it also captured as having MS those with
higher blood pressure and microalbuminuria). Thus, the
most aggressive risk factor management for diabetes
patients might be guided by levels of HDL-c and trigly-
ceride that are sex-specific. For both men and women,
an HDL-c level below 1.0 mmol/L seems to best identify
highest risk. For triglycerides, a level above 1.5 mmol/L
seems appropriate for men, but for women, a much
higher value, such as > 2.5 mmol/L, might be necessary
to identify higher risk.
The limitations to the study are that the analysis was
based on data at study entry, and the proportion of sub-
jects lacking MS features was relatively small. Compari-
sons between those with and without MS thus might
have over- (or under-) estimated effects, but is consis-
tent with other reports[25]. In addition, the average rate
of uptake of statins in the placebo group during follow-
up was substantial (17% over 5 years) [26], and those
with more marked dyslipidemia were most likely to have
had this treatment initiated (21%).
Conclusion
An increasing number of MS variables increased future
CVD risk, and for all definitions, other than the IDF
definition, the risk of CVD among patients defined as
having MS was significantly higher than among those
without. The two MS variables that contributed most to
this risk were HDL-c and hypertension. Waist measure-
ment was not a material contributor. Of current defini-
tions of MS, the WHO definition, which includes
albuminuria, was consistently the best discriminator of
risk, whereas the IDF definition was not significantly
predictive. These results can help guide clinicians in
identifying patients with diabetes at high CVD risk.
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